As a matter of tradition now, this 5th NP2D together with its "Conodays" satellite event will bring together a broad range of scientists from the academia and from the industry who share the same interest for peptide based drugs, even though they come from different horizons and from all around the world. Amongst all participants you will have a real chance to meet with renown scientist and key opinion leaders.

Below is a non-exhaustive list of participant/pre-registred delegations from major companies and institutes such as :

3B Pharmaceuticals Germany), Activen (Switzerland), Airmid (USA), Amgen (USA), Almac Sciences (UK), AstraZeneca (UK), Atheris Laboratories (Switzerland), Aurigene Discovery Technologies Ltd. (India), Axxam SpA (Italy), Bachem (Switzerland), Batelle Memorial Institute (USA), Bioclon (Mexico), Centocor (USA), DebioPharm (Switzerland), Eli Lilly (USA), Estonian Biocenter (Estonia), Eurelations (Switzerland), Ferring (USA), FunZyme BioTechnologies (Switzerland), Genzyme Pharmaceuticals (USA), GlaxoSmithKline (UK), Grenoble Neuroscience Institute (France), HiQScreen (Switzerland), Ironwood Pharmaceuticals (USA), Isogenica (UK), J. Craig Venter Institute (USA), Johnson & Johnson (USA), Lonza (Switzerland), Mannkind Corpration (USA), Medicines for Malaria Venture (Switzerland), MedImmune (UK), MedinCell (France), Nestlé (Switzerland), Nexigen (Germany), Novartis (Switzerland), Novo Nordisk (Denmark), Peptides International (USA), Peptisyntha (Belgium), Pfizer (UK & USA), Polyphor (Switzerland), Phylogica (Australia), Protagonist Therapeutics (USA), Roche (Switzerland), Sanofi-Aventis (France), Shemyakin&Ovchinnikov Institute of bioorganic chemistry (Russian Federation), SmarTox (France), Spheritech (UK), The Scripps Institute (USA), Silanes (Mexico), SiteOne Therapeutics (USA), Solvay (Belgium), Spheritech (UK), Stragen (France), Sygnis Biosciences (Germany), Torrey Pines Institute (USA), Tournoux Biotech (France), Toxinomics Foundation (Switzerland), Unigene Laboratories (USA), Vector Lifesciences (Switzerland), VenomeTech (France), Xenome (Australia), Zealand Pharma (Denmark).

Major Universities from all continents such as those of Brussel, Cadiz, Cincinatti, Florida, Frankfurt, Fribourg, Geneva, Indiana, Jena, Kiel, Leuven, Lisbon, Manila, Monash, Munich, Queensland, Roskilde, Sherbrooke, Singapore,  Tel Aviv, Utah, Utrecht, Vienna, etc. and renown Public Institutions including the Albanian Association of Organic Horticulture, CEA, Centro de Investigación Cientifíca y Educación Superior de Ensenada (CICESE), CNRS, Estonian Biocenter, Haute Ecole Spécialisée de Suisse Occidentale (HES-SO), National Museum of Natural History of Paris, Pasteur Institute, Swiss Institute of Bioinformatics, etc. will also be present with outstanding scientific contributions!

The following people are pre-registred, have already confirmed their attendence, and/or are members of the scientific committee (NP2D and/or Conodays):

• • Luan Ahmetaj, Bioplant Albania, Albania
• • Paul Alewood, University of Queensland, Australia
• • Guenter Allmaier, Vienna University of Technology, Austria
• • Reidar Andreson, Estonian Biocenter, Estonia
• • Francine Andruccioli, Atheris Laboratories, Switzerland
• • Maya Antonin, Atheris Laboratories, Switzerland
• • Christopher Armishaw, Torrey Pines Institute for Molecular Studies, USA
• • Franziska Arnold, Bachem, Switzerland
• • Mimoun Ayoub, Peptisyntha-Solvay, Belgium
• • Maria Bednarek, MedImmune, UK
• • Evelyne Benoit, CNRS, France
• • Johanna Bernaldez, CICESE, Mexico
• • Elise Bernier, Sherbrooke, Canada
• • Daniel Bertrand, HiQScreen, Switzerland
• • Estelle Bianchi, Atheris Laboratories, Switzerland
• • Daniel Biass, Atheris Laboratories, Switzerland
• • Rolf Boelens, University of Utrecht, Netherlands
• • Age Brauer, Estonian Biocenter, Estonia
• • Greg Bulaj, University of Utah, USA
• • Andrew Butler, The Scripps Research Institute, USA
• • Karla Cervantes Luévano, CICESE, Mexico
• • Simon Chell, GlaxoSmithKline, UK
• • Eric Chevalier, Polyphor, Switzerland
  
• • Dennis Church, Toxinomics Foundation & Vector Lifesciences, Switzerland
• • Paul Claudon, Stragen, France
• • Gisela Concepcion, University of Manila, Philippines
• • Sabrina Corazza, Axxam SpA, Italy
• • Graham Cotton, Almac Group, UK
• • David Craik, University of Queensland, Australia
• • Cécile Cros, Atheris Laboratories, Switzerland
• • Coralie De Almeida, Atheris Laboratories, Switzerland
• • Elise de Aquino, Bachem, Switzerland
• • Bonabes de Rougé, Tournoux Biotech, France
  
• • Michel De Waard, Grenoble Neuroscience Institute & SmarTox, France
• • Vladislav Deigin, Shemyakin&Ovchinnikov Institute of bioorganic chemistry, Russian Federation
• • Madiha Derouazi, Geneva University Hospital, Switzerland
• • Michael Dickens, Batelle Memorial Institute, USA
• • Richard DiMarchi, University of Indiana, USA
• • Frédéric Ducancel, CEA-Saclay, France
• • Marc Erhardt, University of Fribourg, Switzerland
• • Emanuel Escher, University of Sherbrooke, Canada
• • Pierre Escoubas, VenomeTech, France
• • Philippe Favreau, Atheris Laboratories, Switzerland
• • Angelika Fretzen, Ironwood, USA
• • Patrick Garrouste, Debio Recherche Pharmaceutique SA, Switzerland
• • Georges Gaudriault, MedinCell, France
• • Nicolas Gilles, CEA-Saclay, France
• • Matthieu Giraud, Lonza, Switzerland
• • Dalia Gordon, University of Tel Aviv, Israël
• • Carsten Grötzinger, Charité - Universitätsmedizin Berlin, Germany
• • Sylvie Guenat, University of Geneva, Switzerland
• • Michael Gurevitz, University of Tel Aviv, Israël
• • Oliver Hartley, University of Geneva and Mintaka Foundation, Switzerland
• • Stefan Heinemann, University of Jena, Germany
• • Christian Heinis, EPFL, Switzerland
• • Hanjo Hennemann, Nexigen, Germany
• • Henry Hocking, University of Utrecht, Netherlands
• • Peter Hoffmann, Consultant, USA
• • Tina Hübscher, Bachem, Switzerland
• • Agnès Jaulent, Isogenica, UK
• • Håvard Jenssen, University of Roskilde, Denmark
• • Manuel Jimenez Tenorio, University of Cadiz, Spain
  
• • Victor Juarez-Perez, Stragen, France
• • Silke Kauferstein, Institute of Legal Medicine, Germany
• • Glenn King, University of Queensland, Australia
• • Eric Kitas, F. Hoffman-La Roche, Switzerland
• • Jacob Kofoed, Novo Nordisk, Denmark
• • Dusan Kordis, Jozef Stefan Institute, Slovenia
• • Dominique Koua, Atheris Laboratories and Swiss Institute of Bioinformatics, Switzerland
• • Kelly Kraft, Mannkind Corporation, USA
• • Thomas Kruse, Novo Nordisk, Denmark
• • Alexander Kurz, Institute of Legal Medicine, Germany
• • Martin Kussmann, Nestlé Institute of Health Sciences, Switzerland
• • Silja Laht, Estonian Biocenter, Estonia
• • Bart Landuyt, University of Leuven, Belgium
• • Bjarne Larsen, Zealand Pharma, Denmark
• • Jesper Lau, Novo Nordisk, Denmark
• • Gildas Lavenant, Almac Group, UK
• • Michel Lazdunski, CNRS, France
• • Andrea Leone-Bay, Mannkind Corporation, USA
• • Richard Lewis, University of Queensland and Xenome Ltd, Australia
• • Alexei Licea, CICESE, Mexico
• • Elza Lopes, Bachem, Switzerland
• • Pavel Lugo, CICESE, Mexico
• • Vera Oldrati, Atheris Laboratories, Switzerland
• • Frank Marí, University of Florida, USA
• • Marc Mathieu, HES-SO, Switzerland
• • Michael McIntosh, University of Utah, USA
• • Dietrich Mebs, Institute of Legal Medicine, Germany
• • Christopher Meenan, Unigene Laboratories, USA
• • Renée Ménez, Toxinomics Foundation, Switzerland
• • George Miljanich, Airmid LLC, SiteOne Therapeutics and Toxinomics Foundation, USA
• • Jordi Molgo, CNRS, France
• • Manfred Mutter, DebioPharm, Switzerland
• • Roman Mylonas, Atheris Laboratories, Switzerland
• • Raymond Norton, Monash University, Australia
• • Origene Nyanguile, HES-SO, Switzerland
• • Robin Offord, Mintaka Foundation for Medical Research, Switzerland
• • Vera Oldrati, Atheris Laboratories, Switzerland
  
• • Araceli Olguin Jimenez, CICESE, Mexico
• • Baldomero Olivera, University of Utah, USA
• • Jorge Paniagua-Solis, Consultant, Switzerland
• • Astrid Pappenberger, F. Hoffman-La Roche, Switzerland
• • Dinseh Patel, Protagonist Therapeutics, USA
• • Michael Pennington, Peptides International and Toxinomics Foundation, USA
• • Frédéric Perret, Atheris Laboratories, Switzerland
• • Sisikumar Pottayil, Aurigene Discovery Technologies Ltd, India
• • Nicolas Puillandre, Atheris Laboratories, Switzerland & Museum of Natural History, France
• • Murali Ramachandra, Aurigene Discovery Technologies Ltd, India
• • Alain Razaname, Debio Recherche Pharmaceutique SA, Switzerland
• • Ulrich Reineke, 3B Pharmaceuticals GmbH, Germany
• • Maido Remm, Estonian Biocenter, Estonia
• • John Ridden, AstraZenecca, UK
  
• • Mario Rottländer, Zealand Pharma, Denmark
• • Daniel Samson, Bachem, Switzerland
• • Gabriel Sandoval Lopez, CICESE, Mexico
• • Armin Schneider, Sygnis Biosciences, Germany
• • Claudio Schteingart, Ferring Research Institute Inc., USA
• • Christian Schütz, Bachem, Switzerland
• • Markus Schwaller, Bachem, Switzerland
• • Jean-Manuel Segura, Life Technologies, HES-SO, Switzerland
  • • • Odile Sellier-Kessler, Polyphor, Switzerland
• • Denis Servent, CEA, France
• • Simon Shell, GlaxoSmithKline, UK
• • Armin Schneider, SYGNIS Bioscience GmbH & Co. KG, Germany
• • Hanna Singer, University of Fribourg, Switzerland
• • Mark Smythe, Protagonist Therapeutics, Switzerland
• • Xavier Sprungli, Toxinomics Foundation, Switzerland
• • Sarah Steiner, Eurelations AG, Switzerland
• • Reto Stöcklin, Atheris Laboratories, Switzerland
• • Sylvie Stöcklin, Atheris Laboratories, Switzerland
• • Tim Stockwell, J. Craig Venter Institute, USA
• • Ronald Swanson, Janssen R&D, USA
• • James Tam, School Biological Sciences, Singapore
• • Heinrich Terlau, University of Kiel, Germany
• • Dirk Tourwe, Vrije Universiteit Brussel, Belgium
• • Sonia Troeira Henriques, University of Lisbon, Portugal
• • Matthias Tschöp, Universities of Cincinatti & Muncih, USA & Germany
• • Peter Verhaert, University of Delft, Netherlands
• • Aude Violette, Atheris Laboratories, Switzerland
• • Maria von Holtey, Debiopharm SA, Switzerland
• • Thomas Vorherr, Novartis Pharma, Switzerland
• • Paul Watt, Phylogica, Australia
• • Don Wellings, Spheritech, UK

We are convinced that this will be an excellent opportunity for your organisation and give you access to great networking opportunities and we warmly encourage you to join us in Zermatt!